Floatz logo

Ebna1 C-Terminal/Lmp2 Chimeric Protein-Expressing Recombinant Modified Vaccinia Ankara Vaccine

Gastric Cancer

Cancer Research UKvaccinePhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
65/ 100

Competitive context

283 Active assets in the Gastric Cancer cohort.

Asset / SponsorPhaseRating
Rivoceranib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4BBB
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 4BB
Eloxatin
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
Capecitabine
I-Mab Biopharma US Limited
Phase 3BB

View all 50 →

Same molecule, other indications

Ebna1 C-Terminal/Lmp2 Chimeric Protein-Expressing Recombinant Modified Vaccinia Ankara Vaccine is also rated in:

lymphoproliferative syndromeDormant
CC
Indicative ·
47 / 100
View asset →
Nonneoplastic ConditionDormant
CC
Indicative ·
47 / 100
View asset →
head and neck cancerDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →